What Happens to Your Gut Microbiome When You Take Antibiotics (and How to Rebuild It)

Antibiotics are one of modern medicine’s greatest achievements. They have saved countless lives and remain essential for treating serious bacterial infections. But there is a side of antibiotic use that is rarely discussed in the clinic: what they do to the ecosystem living inside your gut. The gut microbiome — the vast community of bacteria, fungi, viruses, and other microorganisms residing in your digestive tract — is not a passive bystander during antibiotic treatment. It is profoundly and sometimes permanently affected.

Understanding what happens to your microbiome when you take antibiotics, and what the evidence says about rebuilding it, is one of the most practical things you can do for your long-term health. This guide covers the mechanisms of antibiotic-induced microbiome disruption, the downstream consequences, and an evidence-based, clinical approach to protecting and restoring your gut, including the supplements that can genuinely make a difference.

If at any point while reading this you recognise your own gut history in what we describe, the Ultimate Gut Test and SIBO Breath Test are the most direct way to understand what antibiotic use may have left behind in your specific microbiome.

What Antibiotics Actually Do to Your Gut Microbiome

To understand the impact, it helps to first appreciate what your gut microbiome is doing for you. This ecosystem — comprising trillions of microorganisms — plays a critical role in immune regulation, nutrient metabolism, neurotransmitter production, and protection against pathogens. It is not merely a collection of passengers; it is an active, metabolically complex organ.

When you take antibiotics, particularly broad-spectrum agents, the collateral damage to this ecosystem can be substantial. The research paints a clear picture.

1. Loss of Microbial Diversity

Antibiotic usage is a major cause of profound and long-lasting alterations in the gut microbiome. Broad-spectrum antibiotics cannot selectively target only pathogenic bacteria — they act on whatever microorganisms are sensitive to their mechanism of action, including many beneficial commensal species that form the backbone of your gut community. The result is a sharp reduction in the richness and diversity of your microbiome, often within just days of starting a course.

A landmark study published in Nature Medicine in 2026 — the largest investigation of its kind — combined individual-level prescription data with fecal metagenomics from 14,979 adults to examine the association between antibiotic use over eight years and gut microbiome composition. The findings were striking: antibiotic use within the year before sampling was associated with the greatest reduction in species diversity, but significant associations were also observed for use one to four and four to eight years earlier — and these findings indicate that antibiotics may have long-lasting consequences for the gut microbiome.

Critically, this was not just a cumulative dose effect. A single course of tetracyclines, flucloxacillin, fluoroquinolones, clindamycin, or macrolides taken four to eight years before sampling was associated with lower microbiome species diversity — meaning even one course of the wrong antibiotic can leave a detectable imprint on your microbiome nearly a decade later.

2. Not All Antibiotics Are Equal — And This Matters

One of the most practically useful findings from this body of research is that different antibiotic classes carry very different risks to your microbiome. This is something most patients — and many practitioners — are never told.

Clindamycin, fluoroquinolones, and flucloxacillin accounted for most of the associations with the abundance of individual species, and use of these antibiotics four to eight years earlier was associated with altered abundance of ten to fifteen percent of the species studied.

To put some numbers on this: each course of clindamycin taken within a year before sampling was associated with an average of 47 fewer species detected; each course of fluoroquinolones or flucloxacillin was associated with an average of 20 and 21 fewer species detected respectively.

By contrast, penicillin V, the most-prescribed antibiotic, was associated with ‘only’ 29 species changes, and extended-spectrum penicillins such as amoxicillin showed no significant long-term diversity associations at all.

This has real clinical implications. If you are told you need antibiotics for a dental infection, a skin infection, or a respiratory illness, it is worth asking your prescriber whether a narrower-spectrum option — such as penicillin V — might be appropriate rather than reaching for clindamycin or a fluoroquinolone. The antibiotic that treats the infection is not always the one with the worst microbiome consequences, and in many cases an equally effective but less damaging option exists.

3. Loss of Colonisation Resistance

One of the most clinically significant consequences of antibiotic-induced dysbiosis is the loss of colonisation resistance — the microbiome’s ability to prevent pathogens from establishing a foothold. A healthy gut microbiota, dominated by Firmicutes and Bacteroidetes, suppresses opportunistic bacteria through competition for nutrients, production of inhibitory substances such as short-chain fatty acids and bacteriocins, and stimulation of immune responses.

When this community is disrupted, the gut becomes vulnerable. The most widely cited example is Clostridioides difficile (C. diff) infection — the leading cause of healthcare-associated diarrhoea worldwide. Antibiotic use disrupts the gut microbiota, leading to decreased colonisation resistance and opportunistic proliferation of non-native organisms — with C. difficile infection being one of the most common and potentially serious antibiotic-induced sequelae. Clindamycin, penicillins, cephalosporins, and fluoroquinolones appear to pose the greatest risk — a finding directly corroborated by the 2026 Nature Medicine study.

Disrupted colonisation resistance also creates conditions where Candida albicans and other opportunistic fungi can overgrow, and where Gram-negative Proteobacteria — often associated with systemic inflammation — can expand into the vacated ecological space.

4. Depletion of Butyrate-Producing Bacteria

Among the most consequential casualties of antibiotic treatment are the butyrate-producing bacteria — species such as Faecalibacterium prausnitzii, Roseburia spp., and members of the Lachnospiraceae family. These anaerobic bacteria ferment dietary fibre to produce butyrate, a short-chain fatty acid that serves as the primary energy source for colonocytes (the cells lining your colon). Butyrate reinforces intestinal barrier function, regulates goblet cell mucus production, and exerts potent anti-inflammatory effects via histone deacetylase inhibition.

The 2026 Nature Medicine paper found that flucloxacillin was primarily associated with disruption of bacteria in the orders Lachnospirales and Oscillospirales — precisely the orders that contain the majority of butyrate-producing species. Clindamycin and fluoroquinolones showed an even broader impact across multiple phyla.

Disruptions to butyrate-producing bacteria, which are correlated with antibiotic exposure, are linked to gut dysbiosis and associated with a wide spectrum of chronic diseases, including inflammatory bowel disease, obesity, type 2 diabetes, neurodegenerative disorders, and psychiatric conditions. The loss of butyrate also impairs the anaerobic environment of the colon — raising oxygen tension in a way that paradoxically favours more oxygen-tolerant, potentially pathogenic organisms.

5. Long-Term Cardiometabolic Consequences

The 2026 Nature Medicine study went beyond microbiome composition to examine whether the species changes caused by antibiotics were linked to cardiometabolic health markers. The findings are sobering. Use of clindamycin, fluoroquinolones, and flucloxacillin was associated with a greater abundance of species including Enterocloster bolteae, Flavonifractor plautii, Ruminococcus B gnavus, and Eggerthella lenta — species that have been associated with higher BMI, serum triglycerides, and risk of type 2 diabetes. Conversely, the species depleted by these antibiotics — including Faecalibacterium prausnitzii and Alistipes communis — were associated with healthier cardiometabolic profiles.

The authors noted that their results align with the hypothesis that antibiotic-induced alterations in the gut microbiome may contribute to the development of cardiometabolic diseases — a mechanism that has been proposed to explain the well-documented epidemiological associations between antibiotic use and increased risk of obesity, type 2 diabetes, and cardiovascular disease.

6. Disruption of the Gut-Brain Axis

The gut microbiome communicates bidirectionally with the brain via the vagus nerve, immune signalling, and microbial metabolites — a pathway known as the gut-brain axis. Research has demonstrated that mice receiving broad-spectrum antibiotics display significant impairments in spatial memory tasks and abnormal encoding of space, accompanied by altered brain metabolism and increased blood-brain barrier permeability — effects linked to depletion of gut microbiome-derived short-chain fatty acids, particularly butyrate. Emerging evidence also associates dysbiosis with systemic conditions including chronic inflammation, metabolic syndrome, and neurodegenerative disease, underscoring the relevance of the microbiota-gut-brain axis.

How Long Does Recovery Take? Much Longer Than You Think

This is one of the most common questions I hear in clinical practice — and the honest answer, supported by the most robust evidence to date, is far more sobering than the “a few weeks” message most people receive.

The 2026 Nature Medicine study is the most definitive population-level data we have on this question. Its functional regression modelling showed that gut microbiome diversity recovered most rapidly within the first two years following antibiotic exposure, with a markedly slower recovery observed in subsequent years — and this pattern was evident for species richness after clindamycin, fluoroquinolone, and tetracycline use.

Moreover, the recovery rate in the period following antibiotic use was proportional to the magnitude of the initial reduction in diversity — meaning the more damage done, the harder and slower the recovery. And for a significant proportion of individuals, a full recovery might take years, with some species changes still detectable four to eight years after a single course.

Interindividual variation is substantial. In studies of cohabiting adults, fluoroquinolones caused transient changes with recovery within a week for most participants — but approximately a quarter showed long-lasting effects, including colonisation by external strains more than two years after exposure.

There is also an important distinction between structural recovery (species returning to pre-treatment levels) and functional recovery (restoration of full metabolic outputs, including butyrate production and bile acid metabolism). These may not occur simultaneously, and functional deficits can persist even when diversity metrics appear to have normalised.

The practical implication is that a two-week post-antibiotic probiotic course is not a meaningful recovery intervention. The gut microbiome needs sustained, long-term dietary and nutritional support — which is precisely what the evidence-based protocol below is designed to provide.

The Problem With Standard Probiotic Advice

The reflexive recommendation to “just take a probiotic” during antibiotics is well-intentioned but increasingly questioned by the evidence.

Most commercial probiotics contain species such as Lactobacillus acidophilus or Bifidobacterium longum. While they may transiently confer benefits, the most rigorous research suggests that multi-strain probiotic supplements taken immediately after antibiotics can actually delay the return of native microbial communities. In one influential study, the antibiotic-perturbed gut was effectively colonised by the probiotic strains, which then crowded out — rather than facilitated — the re-establishment of the indigenous microbiota.

This does not mean all probiotics are without value in this context. Rather, the evidence calls for a more nuanced, evidence-stratified approach — which is outlined below.

An Evidence-Based Protocol: Protecting and Rebuilding Your Gut

Below is the clinical framework I use with patients who are taking or have recently completed antibiotics. The goal is threefold: protect the gut environment during the antibiotic course, prevent opportunistic overgrowth, and actively support the return of a diverse, functional microbiome. Given what we now know about recovery timelines, this is not a short-term intervention.

During Antibiotics

1. Saccharomyces boulardii

This is the single most evidence-supported supplement to take during a course of antibiotics. Saccharomyces boulardii (strain CNCM I-745) is a probiotic yeast, not a bacterium — and this distinction matters enormously. Because it is a yeast, it is intrinsically resistant to antibiotics and is not inhibited or killed by them the way bacterial probiotic strains would be.

The evidence base is substantial. A meta-analysis of 21 randomised controlled trials involving 4,780 participants confirmed that S. boulardii is effective in reducing the risk of antibiotic-associated diarrhoea in both children and adults. Across 31 randomised placebo-controlled treatment arms in 27 trials encompassing over 5,000 patients, S. boulardii was found to be significantly efficacious and safe in 84% of those treatment arms, with a pooled relative risk for antibiotic-associated diarrhoea of 0.47 — essentially cutting the risk of diarrhoea in half.

When comparing probiotic strains for the prevention of antibiotic-associated diarrhoea, S. boulardii tends to outperform other strains and is associated with the fewest adverse effects, making it a strong first-line choice.

Beyond its anti-diarrhoeal properties, S. boulardii appears to work by promoting the gut environment itself — including SCFA production and mucosal integrity — without blocking the return of native microbial communities. This is precisely the behaviour we want during a course of antibiotics whose effects, as we now know, may persist for years.

Clinical note: Take S. boulardii at least 2 hours away from your antibiotic dose. Continue for at least 4 weeks after completing the course.

Recommended Product: S. Boulardii

2. Tributyrin / Butyrate Supplementation

Given that antibiotics — particularly clindamycin, fluoroquinolones, and flucloxacillin — specifically deplete the Lachnospirales and Oscillospirales species responsible for butyrate production, directly supplementing with butyrate during and after a course is one of the most logical and mechanistically sound interventions available.

Research over the past two decades has demonstrated the beneficial effects of butyrate on gut immune function and epithelial barrier function, with most preclinical and clinical studies showing a positive effect of butyrate oral supplements in reducing inflammation and maintaining remission.

Breakthrough research has shown that butyrate supplementation preserves spatial cognition, neural dynamics, and blood-brain barrier function in antibiotic-treated animals — highlighting that its protective effects extend well beyond the gut itself, with direct relevance to the cognitive and neurological consequences of antibiotic-induced dysbiosis.

Dietary interventions involving butyrate supplementation have been shown to alleviate antibiotic-induced gut dysbiosis and barrier injuries.

Tributyrin is a triglyceride form of butyrate that offers superior bioavailability compared to sodium butyrate, as it resists breakdown in the upper gastrointestinal tract and delivers butyrate to the colon where it is needed most. Delayed-release formulations are preferable for the same reason.

Given the evidence that butyrate-producing species may remain depleted for years after certain antibiotic courses, butyrate supplementation is not simply a short-term bridge — it is a meaningful medium-term intervention.

You can read our deep dive in to butyrate here.

Clinical note: Begin butyrate supplementation on the first day of your antibiotic course. Given the extended recovery timelines now established in the literature, continue for a minimum of 3 months after completing the course, or until comprehensive stool testing confirms restoration of butyrate-producing species.

Recommended Product: Sodium Butyrate or Tributyrin.

3. Zinc

Zinc is an often-overlooked but critical micronutrient for gut barrier integrity. A patient-based clinical study found that orally administered zinc gluconate significantly modified tight junction protein expression in the intestinal epithelium — notably Claudin-2 and Tricellulin — and reduced passive intestinal leak as measured by serum D-lactate levels, suggesting it can induce meaningful remodelling of the gut barrier.

Animal research has specifically demonstrated that zinc gluconate protects against antibiotic-induced intestinal mucosal barrier damage — restoring tight junction proteins, reducing gut permeability, suppressing inflammatory NF-κB signalling, and partially restoring microbiome diversity and richness.

Intestinal permeability is modified by nutrients including zinc, glutamine, vitamin D, and polyphenols, all of which have been shown to decrease permeability and support barrier repair.

Available in our clinic: We stock zinc in bisglycinate and gluconate forms. Typical short-term dose: 15–25 mg elemental zinc daily with food. Avoid prolonged high-dose supplementation without monitoring copper status.

Recommended Product: Zinc 15 or Rezcue (a glutamine & zinc carnosine combo)

4. L-Glutamine

Glutamine is the most abundant amino acid in the bloodstream and the primary fuel source for enterocytes — the cells lining the small intestinal wall. Glutamine plays a critical role in activating mTOR cell signalling in enterocytes, promoting enterocyte proliferation and survival, and regulating intestinal barrier function in injury, infection, and other catabolic conditions.

Glutamine administration has been shown to improve outcomes in critically ill patients, presumably by maintaining physiological intestinal barrier integrity and reducing the frequency of infections. Glutamine levels can become depleted during periods of physiological stress, making supplementation particularly relevant in the post-antibiotic recovery period when the gut mucosa is under sustained strain.

Recommended Product: Rezcue

After Antibiotics: Rebuilding the Microbiome

A Microbiome-Supportive Diet — Your Most Powerful Long-Term Tool

Diet is perhaps the most powerful tool for microbiome recovery — and one that is almost entirely within your control. Emerging research suggests that diet-induced dysbiosis predisposes the microbiome to collapse after antibiotic perturbation, and that diet plays a significant role in driving the ecology of recovery and community diversification. Given that full microbiome recovery may take years, dietary habits are not a short-term intervention — they are the foundation of long-term restoration.

Key dietary principles during and after antibiotics:

Prioritise prebiotic fibres. Prebiotic-rich foods — garlic, onions, leeks, asparagus, Jerusalem artichoke, green banana, and oats — selectively feed the commensal bacteria trying to re-establish themselves, including the butyrate-producing Lachnospirales and Oscillospirales species most severely depleted by clindamycin, flucloxacillin, and fluoroquinolones. A low-fibre diet may exacerbate the impact of antibiotics on the gut microbiome and delay recovery, while prebiotic fibres may promote the growth of beneficial gut microorganisms and boost the production of short-chain fatty acids following antibiotics. Introduce fibre gradually, however, as a disrupted microbiome may struggle to ferment large quantities immediately.

Fermented foods. Consuming foods rich in fermentable fibre after completing an antibiotic course may help restore healthy gut bacteria and is associated with reduced antibiotic resistance. Incorporate plain kefir, unsweetened live yoghurt, kimchi, sauerkraut, and miso consistently during your recovery period.

Eliminate refined sugars and ultra-processed foods. These can feed pathogenic organisms competing for space in the disrupted post-antibiotic gut. Remove them while your microbiome is recovering.

Adequate protein and healthy fats. Support enterocyte regeneration and mucosal healing with high-quality proteins (oily fish, pastured eggs, legumes) and anti-inflammatory fats (extra virgin olive oil, oily fish, avocado).

Polyphenol-Rich Foods

Polyphenols — plant compounds found in berries, dark chocolate, green tea, pomegranate, and extra virgin olive oil — have prebiotic properties and support the growth of beneficial bacteria including Akkermansia muciniphila and Bifidobacterium species. They also exert anti-inflammatory effects at the gut mucosal level, and some evidence suggests they can promote the re-establishment of commensal communities in the post-antibiotic environment. Including a wide variety of colourful plant foods is one of the simplest ways to increase your polyphenol intake during recovery.

Consider Targeted Microbiome Testing

Given what we now know about recovery timelines — that meaningful microbiome disruption may persist for years — a one-size-fits-all post-antibiotic protocol is not the most clinically rational approach. Comprehensive gut microbiome testing allows us to understand your specific landscape and target interventions accordingly.

Every gut is unique. Your intervention should be too

Get real answers, shop tests.

A Note for Those with SIBO, IMO, or Recurrent Gut Issues

If you are treating a known condition such as SIBO (Small Intestinal Bacterial Overgrowth) or IMO (Intestinal Methanogen Overgrowth) with antibiotics such as rifaximin or neomycin, the microbiome recovery protocol above still applies — with some important nuances.

The goal of antibiotic treatment for SIBO/IMO is to reduce the abnormal bacterial overgrowth in the small intestine. However, this does not mean the downstream microbiome is unaffected. Supporting butyrate production, gut barrier integrity, and colonisation resistance is just as important in this clinical context — and the evidence that even a single antibiotic course can have effects detectable years later gives additional weight to a thorough, sustained recovery approach.

SIBO recurrence is common and is often driven by the same root-cause factors that created the original overgrowth — including impaired migrating motor complex function, low stomach acid, bile insufficiency, or structural issues. Antibiotic treatment without addressing these root causes is unlikely to produce lasting results.

How Long Should You Follow the Recovery Protocol?

Based on the evidence — including the 2026 Nature Medicine data showing measurable microbiome disruption up to eight years after certain antibiotic courses — the post-antibiotic recovery window is considerably longer than previously appreciated. As a general clinical framework:

• S. boulardii: Begin day one of antibiotics; continue for a minimum of 4 weeks post-course
• Butyrate/tributyrin: Begin day one of antibiotics; continue for at least 3 months post-course, or until stool testing confirms restoration of butyrate-producing species — particularly if you took clindamycin, a fluoroquinolone, or flucloxacillin
• Zinc: 4–6 weeks post-antibiotics
• L-glutamine: 4–8 weeks post-course
• Dietary strategies: Maintain ongoing — these are a long-term microbiome investment, not a short-term fix
• Microbiome testing: Consider 8–12 weeks after (minimum 28 days) completing antibiotics to guide further targeted intervention

Factors that may prolong recovery include a previously compromised microbiome, multiple previous antibiotic courses, high-stress periods, poor diet quality, or use of the high-impact antibiotic classes identified in the research: clindamycin, fluoroquinolones (e.g. ciprofloxacin, levofloxacin), and flucloxacillin.

Summary: Key Takeaways

• Antibiotics cause profound and potentially very long-lasting disruption to the gut microbiome — the largest study to date found measurable effects up to eight years after a single course of certain antibiotics
• Not all antibiotics are equal: clindamycin, fluoroquinolones, and flucloxacillin cause the most severe and durable damage; penicillin V and amoxicillin have a significantly lower impact
• Recovery is highly variable, diet-dependent, and may take years — not weeks — for the most damaging antibiotic classes
• Standard multi-strain bacterial probiotics may delay rather than support post-antibiotic microbiome recovery
• Saccharomyces boulardii is the most robustly evidence-supported supplement to take during a course of antibiotics
• Tributyrin/butyrate supplementation supports gut barrier integrity, mucosal recovery, and colonocyte health — and should be continued for at least 3 months after high-impact antibiotic courses
• Zinc and L-glutamine support tight junction repair and enterocyte integrity
• A prebiotic- and fibre-rich diet is the most powerful long-term tool for microbiome restoration
• Comprehensive stool testing can personalise your recovery plan and identify whether key butyrate-producing species have returned

Disclaimer: This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare practitioner before making changes to your supplement regimen or treatment plan.

References

1. Baldanzi G, Larsson A, Sayols-Baixeras S, et al. Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals. Nat Med. 2026;32:1351–1361. doi:10.1038/s41591-026-04284-y.
2. Cusumano G, Angeles Flores G, Venanzoni R, Angelini P. The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies. Antibiotics. 2025;14(4):371. doi:10.3390/antibiotics14040371.
3. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202–2222. PMID: 20458757.
4. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42(7):793–801. PMID: 26216624.
5. Johanesen PA, Mackin KE, Hutton ML, et al. Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance. Genes. 2015;6(4):1347–1360. PMID: PMC4690045.
6. Theriot CM, Young VB. Clostridium difficile and the microbiota. Annu Rev Microbiol. 2015;69:445–461. PMID: 25036699.
7. Zhao T, et al. Butyrate-Producing Bacteria as a Keystone Species of the Gut Microbiome. Nutrients. 2025. PMID: PMC12897970.
8. Sun Y, et al. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Pharmaceutics. 2023;15(5):1386. PMID: 37242159.
9. Camilleri M. Intestinal Barrier Impairment, Preservation, and Repair: An Update. Am J Gastroenterol. 2024. PMID: 39458489.
10. Ma X, et al. Protective effect of zinc gluconate on intestinal mucosal barrier injury in antibiotics and LPS-induced mice. Front Microbiol. 2024. PMID: PMC11157515.
11. Patel MI, Bhutta ZA. Glutamine and intestinal barrier function. Amino Acids. 2015;47(10):2143–2154. PMID: 24965526.
12. Butyrate preserves entorhinal-hippocampal spatial coding and blood-brain barrier integrity in mice with depleted gut microbiome. PMC. 2025. PMID: PMC12324207.
13. Dahiya D, Nigam PS. Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition. Int J Mol Sci. 2023;24(3):3074. PMID: PMC9959899.
14. FitzGerald J, et al. Improved gut microbiome recovery following drug therapy is linked to abundance and replication of probiotic strains. Gut Microbes. 2022;14(1). PMID: PMC9348039.
15. Zarrinpar A, et al. Diet outperforms microbial transplant to drive microbiome recovery post-antibiotics. bioRxiv. 2024.